ReviewClinical interventions in aging2025
The Ambiguous Role of HMGB1 Across the Hallmarks of Aging: A Narrative Review.
Review in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammaging and cytokine-driven cardiovascular senescence in age-related myocardial infarction: mechanisms, biomarkers, and precision immunotherapy strategies.Biogerontology · 2026Review
- Longevity Aesthetics: A Conceptual Framework for Integrating Pro-Aging Medicine Into Surgical and Nonsurgical Practice.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a complex, multifactorial process driven by interconnected biological mechanisms collectively known as the hallmarks of aging, which contribute to functional decline and the onset of age-related diseases. High-mobility group box 1 (HMGB1), a nuclear DNA chaperone and damage-associated molecular pattern (DAMP), plays a pivotal role in regulating these hallmarks through its dual functions: preserving genomic stability within the nucleus and promoting inflammatory responses when released extracellularly. This review examines the multifaceted involvement of HMGB1 in key aging hallmarks, such as genomic instability, telomere attrition, mitochondrial dysfunction, and chronic inflammation among others. Preclinical studies demonstrate that nuclear HMGB1 supports chromatin integrity and DNA repair, whereas its extracellular release triggers TLR4/RAGE signaling pathways, thereby intensifying inflammaging and senescence-associated secretory phenotypes (SASP). Emerging therapeutic approaches-such as HMGB1 inhibitors, neutralizing antibodies, and epigenetic modulators-show potential in restoring genomic homeostasis and mitigating age-related pathologies. Nevertheless, significant challenges remain, including elucidating HMGB1's roles in nutrient sensing and psychosocial stress, fine-tuning interventions to preserve its nuclear functions while minimizing extracellular toxicity, and establishing efficacy in human clinical settings. Addressing these gaps may position HMGB1 as a promising multifunctional target for delaying aging and translating preclinical findings into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.